欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

开市前 08-11 09:19:30

5.485

+0.000

0.00%

最高5.485	最低5.485	成交量0.00
今开5.485	昨收5.485	日振幅0.00%
总市值44.70亿	流通市值44.70亿	总股本8.15亿
成交额0.00	换手率0.00%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.485,"timestamp":1786410001293,"preClose":5.485,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":815000000,"shares":815000000,"eps":-0.23259087235895468,"marketStatus":"开市前","change":0,"latestTime":"08-11 09:19:30","open":5.485,"high":5.485,"low":5.485,"amount":0,"amplitude":0,"askPrice":5.59,"askSize":10000,"bidPrice":5.3,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":-0.23344331790615022,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786411800000},"marketStatusCode":1,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.485,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2658293290","title":"汇宇制药（688553）披露子公司产品获得境外上市许可公告，8月10日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658293290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658293290?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:20","pubTimestamp":1786371625,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，汇宇制药报收于12.04元，较前一交易日上涨1.09%，最新总市值为75.36亿元。近日，四川汇宇制药股份有限公司子公司Seacross Pharma Ltd.收到德国、荷兰、西班牙药品监管机构核准签发的注射用帕瑞昔布钠和唑来膦酸注射液上市许可。注射用帕瑞昔布钠获德国上市许可，规格为40mg；唑来膦酸注射液获荷兰和西班牙上市许可，规格均为4mg/100ml。上述产品已在多个国家获批上市，公司已开展上市销售前期准备。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000034137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1574","BK0239","688553","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658698026","title":"歌礼制药-B(01672)在美国启动两项治疗肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658698026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658698026?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:53","pubTimestamp":1786359237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在获得美国食品药品监督管理局新药临床试验申请批准后，其已在美国启动了两项治疗肥胖症的I期研究：每月一次至每季度一次的新一代胰淀素受体激动剂多肽ASC36，以及ASC36和GLP-1R/GIPR 双靶点激动剂多肽ASC35的皮下固定剂量复方月注射剂ASC36_35FDC。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1515","BK1161","BK1574","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658984441","title":"汇宇制药(688553.SH)：注射用帕瑞昔布钠、唑来膦酸注射液获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2658984441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658984441?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:30","pubTimestamp":1786354254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药(688553.SH)发布公告，公司子公司Seacross(Europe)Pharma Ltd.于近期分别收到德国联邦药品和医疗器械管理局、荷兰健康产品监管局、西班牙药品和医疗器械管理局分别核准签发的公司产品注射用帕瑞昔布钠、唑来膦酸注射液的上市许可。据悉，注射用帕瑞昔布钠是一种普通制剂，用于成人术后短期疼痛的治疗。唑来膦酸注射液主要用于预防成人晚期恶性肿瘤骨转移患者的骨骼相关事件(病理性骨折、脊髓压迫、需接受放疗或手术的骨病变，或肿瘤引起的高钙血症)和治疗成人肿瘤引起的高钙血症(TIH)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","BK1191","BK1574","01477","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658989397","title":"国投证券：制药装备迎新一轮提质改革期 国内头部企业重点关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2658989397","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658989397?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:12","pubTimestamp":1786349576,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国投证券发布研报称，制药装备行业规模稳定增长，生物工艺基于单抗、疫苗、CGT细胞基因治疗、GLP-1多肽、合成生物等赛道的快速发展，已成为制药装备行业规模增长的重要推动力。政策、需求及市场共同推动国内制药装备企业迎来新一轮增长机遇，国内头部企业重点关注。投资建议聚焦高端国产替代和具备全球化商业布局能力的企业，重点关注东富龙和楚天科技。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1191","161027","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658602886","title":"A股异动 | 华大智造(688114.SH)大涨超19% AI4S进入产业化阶段 公司为AI制药提供基础工具测序仪","url":"https://stock-news.laohu8.com/highlight/detail?id=2658602886","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658602886?lang=zh_cn&edition=full","pubTime":"2026-08-10 12:00","pubTimestamp":1786334434,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华大智造早盘大涨超19%，截至发稿，涨14.27%，报61.51元，成交额10.14亿元。消息面上，AI for Science正从概念走向产业化拐点。据悉，华大智造作为全栈生命科技工具提供商，全读长测序仪业务全球领先，为AI制药提供基础工具测序仪，此前曾与追光生物、新加坡国立大学药学与制药科学系在药物研发及药学研究等方面达成合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","QTOC","CHAT","AGIX","BK0251","688114","399300","159982","AIPO","BK1574","ARTY","BK1191","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604503","title":"金斯瑞生物科技盘中涨超8% 全球AI制药落地进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604503","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658604503?lang=zh_cn&edition=full","pubTime":"2026-08-10 11:26","pubTimestamp":1786332360,"startTime":"0","endTime":"0","summary":"全球AI制药落地进入兑现期。美股Twist中报业绩超预期，AI相关订单同比翻倍增长，全年营收指引上调至4.56-4.57亿美元。据悉，金斯瑞生命科学事业群覆盖DNA合成、蛋白生产、抗体开发及功能验证，可以将AI生成序列进一步转化为实体蛋白及实验数据。AI驱动药物开发及多抗体药物开发需求增长，带动基因至蛋白业务快速成长；2025年生命科学事业群收入5.22亿美元，同比增长14.8%，同时持续扩大自动化、数字化生产能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-10/doc-inimuzxp1267880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01548","BK1141","BK1191","AGIX","CHAT","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","BK1576","BK1574","ARTY","VTHR","QTOC","AIPO","01477","HK0000320223.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658760922","title":"英硅智能盘中涨超11% AI制药正由概念探索进入需求验证期","url":"https://stock-news.laohu8.com/highlight/detail?id=2658760922","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658760922?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:08","pubTimestamp":1786327680,"startTime":"0","endTime":"0","summary":"东财医药唐爱金团队观点指出，AI制药对医药产业的再定价不是“替代湿实验”，而是“放大验证流量+重塑研发分工”。另据国海证券测算2020—2025年全球AI技术交易数量CAGR达到30.7%，显著高于医药整体交易增速；2026年至今交易数量已超过2025年全年，AI制药正由概念探索进入需求验证期。国泰海通证券指出，英硅智能是全球领先的AI制药先行者，利用其自主研发的生成式人工智能平台Pharma.AI实现端到端的药物研发全流程赋能。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-10/doc-inimuvrv5038041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIPO","ARTY","CHAT","QTOC","BK1574","AGIX","01477","BK1191","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658015776","title":"港股异动 | AI和创新药双向加持 剂泰科技-P(07666.HK)早盘涨超19% 继续领涨AI制药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2658015776","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658015776?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:05","pubTimestamp":1786327542,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06978","BK1161","01477","07666","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360953","title":"港股异动 | 英硅智能(03696.HK)盘中涨超11% AI制药进入需求验证期 公司端到端全流程覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360953","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658360953?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:37","pubTimestamp":1786325874,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03696","BK1574","BK1191","01477","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658053586","title":"中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658053586","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658053586?lang=zh_cn&edition=full","pubTime":"2026-08-10 07:40","pubTimestamp":1786318852,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1574","01477","VTHR","AGIX","AIPO","BK0276","CHAT","601066","ARTY","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658707436","title":"股市必读：汇宇制药新发布《关于控股股东、实际控制人部分股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658707436","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658707436?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:52","pubTimestamp":1786297933,"startTime":"0","endTime":"0","summary":"公司公告汇总：控股股东拟向控股子公司汇宇悦迎提供3000万元无担保借款，年利率2.6%，低于同期LPR，依规免于关联交易审议程序。公司公告汇总关于控股股东、实际控制人部分股份质押的公告四川汇宇制药股份有限公司控股股东、实际控制人丁兆先生持有公司股份168,818,814股，占公司总股本的26.97%。本次质押7,500,000股，占其所持股份的4.44%，占公司总股本的1.20%。质押股份用于支持控股子公司日常经营所需资金，质权人为华夏银行股份有限公司成都金牛支行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673625","title":"每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673625?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:21","pubTimestamp":1786209669,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，泽璟制药报收于121.7元，较上周的122.1元下跌0.33%。本周，泽璟制药8月7日盘中最高价报122.0元。本周关注点来自业绩披露要点：公司自成立以来首次实现半年度盈利，归母净利润为64,001.11万元。机构调研要点2026年上半年，公司实现营业收入120,537.96万元，同比增长220.88%，主要因确认技术授权收入66,230.95万元及商业化产品销售增长；归母净利润达64,001.11万元，首次实现半年度盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1191","BK1574","688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625992","title":"泽璟制药获得发明专利授权：“氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625992","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657625992?lang=zh_cn&edition=full","pubTime":"2026-08-08 03:38","pubTimestamp":1786131538,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示泽璟制药新获得一项发明专利授权，专利名为“氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用”，专利申请号为CN202011367513.8，授权日为2026年8月7日。今年以来泽璟制药新获得专利授权4个，较去年同期增加了100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644613","title":"汇宇制药（688553）披露控股股东部分股份质押公告，8月7日股价上涨7.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644613?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:22","pubTimestamp":1786112575,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，汇宇制药报收于11.91元，较前一交易日上涨7.59%，最新总市值为74.54亿元。近日，汇宇制药披露《关于控股股东、实际控制人部分股份质押的公告》。公告显示，公司控股股东、实际控制人丁兆先生持有公司股份168,818,814股，占公司总股本的26.97%。本次质押7,500,000股，占其所持股份的4.44%，占公司总股本的1.20%。本次质押后，丁兆先生累计质押股份为7,500,000股，无股份被用作重大资产重组或业绩补偿担保，亦不存在潜在业绩补偿义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","01477","688553","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657148526","title":"中邮证券：首次覆盖泽璟制药给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657148526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657148526?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:48","pubTimestamp":1786096123,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对泽璟制药进行研究并发布了研究报告《商业化产品快速放量，研发全面开花》，首次覆盖泽璟制药给予买入评级。公司商业化产品矩阵处于放量期，在研双/多抗临床数据优势明显，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为141.08。本文数据来源于中邮证券有限责任公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700030922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616355","title":"8月7日泽璟制药涨8.45%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616355?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092082,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日泽璟制药涨8.45%，收盘报121.7元，换手率3.44%，成交量9.11万手，成交额10.75亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共110家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为89.62亿元，最新净值1.7141，较上一交易日上涨1.23%，近一年下跌15.27%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477","BK1515","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657516695","title":"港股异动 | AI制药商业化兑现能力逐步凸显 剂泰科技-P(07666.HK)大涨超7%领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657516695?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:51","pubTimestamp":1786074686,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1191","BK1161","01477","07666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521991","title":"股市必读：浙江震元新发布《关于为子公司震元制药提供担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657521991?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:37","pubTimestamp":1785951430,"startTime":"0","endTime":"0","summary":"公司公告汇总：浙江震元为全资子公司震元制药提供最高额30,000万元连带责任保证，担保期限五年，截至公告日实际担保额度71,000万元，占公司2025年经审计净资产的35.95%。公司公告汇总关于为子公司震元制药提供担保的进展公告2026年8月3日，浙江震元与中信银行绍兴分行签署《最高额保证合同》，为全资子公司震元制药在2026年8月3日至2031年8月3日期间向中信银行申请的最高额30,000万元人民币贷款提供连带责任保证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000705","01477","BK0250","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657454762","title":"开源证券：给予泽璟制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657454762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657454762?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:00","pubTimestamp":1785934844,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,聂媛媛近期对泽璟制药进行研究并发布了研究报告《公司信息更新报告：2026H1-ZG006海外授权兑现价值，加速全球化》，给予泽璟制药买入评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为141.08。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657471745","title":"九洲药业：近年来公司新增承接3家全球头部跨国制药企业的项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2657471745","media":"证券日报 ","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657471745?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:17","pubTimestamp":1785932220,"startTime":"0","endTime":"0","summary":"证券日报网8月5日讯 ，九洲药业在接受调研时表示，公司持续深化与核心战略客户的合作，巩固存量业务基础。公司与部分全球大型制药企业建立了长期稳定的合作关系，除持续供应成熟商业化项目外，每年还承接多个不同阶段的创新药项目。国内市场方面，公司持续为多家头部创新药企业提供CDMO服务，合作逐步向临床后期及商业化阶段延伸。新客户拓展方面，公司持续推进全球大型制药企业及优质Biotech公司开发。近年来，公司新增承接3家全球头部跨国制药企业的项目，并持续深化与其他海外大型制药企业的合作；同时，国内创新药客户数量持续增加，临床中后期项目不断导入。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-05/doc-inimhpmz5094040.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-05/doc-inimhpmz5094040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603456","BK0070","BK0239","BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0819},{"period":"3month","weight":-0.2275},{"period":"6month","weight":-0.2085},{"period":"1year","weight":-0.4811},{"period":"ytd","weight":-0.2588}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0729},{"period":"3month","weight":-0.0156},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0434},{"period":"ytd","weight":0.012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003589},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.043623},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}